Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinoid isomerohydrolase RPE65 is an enzyme found in the retinal pigment epithelium that is essential for the visual cycle, specifically required for regenerating 11-cis-retinal from all-trans-retinyl esters; this step is crucial for phototransduction and sustaining normal vision. Mutations in the RPE65 gene are responsible for several inherited retinal diseases, including Leber congenital amaurosis and retinitis pigmentosa, leading to severe visual impairment or blindness. The enzyme's central role in vitamin A metabolism and retinal health has made it the target for gene therapy—for example, voretigene neparvovec, a gene addition therapy approved for patients with confirmed biallelic pathogenic RPE65 mutations[1][2][3][4].
Restoration of functional RPE65 activity (via gene addition therapy, such as voretigene neparvovec), facilitating the conversion of all-trans-retinyl esters to 11-cis-retinol for visual pigment regeneration
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinoid isomerohydrolase RPE65 (RPE65).